106166-01-2

Upstream product

• 931-51-1 cyclohexylmagnesiumchloride 
• 1122-91-4 4-bromo-benzaldehyde 
• 106-37-6 1.4-dibromobenzene 
• 2043-61-0 cyclohexanecarbaldehyde 
• 110-82-7 cyclohexane 
• 36140-19-9 dicyclohexylboron chloride 
• 931-50-0 cyclohexylmagnesium bromide 

Downstream Products

• 3277-79-0 (4-bromophenyl)(cyclohexyl)methanone 
• 1158041-63-4 1-(4-bromophenyl)-1-cyclohexylethanol 
• 263257-26-7 cyclohexyl(4-(2-quinol-2-ylethenyl)phenyl)methanol O-tertbutyldimethylsilyl ether 
• 263256-92-4 cyclohexyl(4-(2-quinol-2-ylethyl)phenyl)methanol 
• 1027056-41-2 O-{cyclohexyl-[4-(2-quinolin-2-yl-ethyl)-phenyl]-methyl}-hydroxylamine 
• 263256-90-2 cyclohexyl(4-(2-quinol-2-ylethenyl)phenyl)methanol 
• 263256-89-9 cyclohexyl(4-formylphenyl)methanol tert-butyldimethylsilyl ether 
• 263257-25-6 (4-bromophenyl)cyclohexylmethanol O-tert-butyldimethylsilyl ether 

Relevant academic research and scientific papers

Coupling Reaction between Aldehydes and Non-Activated Hydrocarbons via the Reductive Radical-Polar Crossover Pathway

Herein, we describe the generation of an organochromium-type carbanion species from a non-activated C-H bond and its nucleophilic addition to aldehydes. The catalytic carbanion generation occurred through formal deprotonation of a non-activated C-H bond under mild conditions and did not need the prefunctionalization or anion stabilizing group. Carbon radical intermediates generated by decatungstate photocatalyst-mediated hydrogen abstraction were captured by a chromium salt with the reductive radical-polar crossover reaction to produce organochromium carbanions.

HYDROXY SUBSTITUTED ISOQUINOLINONE DERIVATIVES

The invention relates to compounds of formula (I): as defined in the application. Such compounds are suitable for the treatment of a disorder or disease which is mediated by the activity of MDM2 and/or MDM4, or variants thereof.

12-ARYL PROSTAGLANDIN ANALOGS

Compounds comprising the formula (I) are disclosed, wherein Y, A, X, R, D, and n are as described. A compound comprising a prostaglandin EP2 selective agonist wherein the ω-chain comprises a substituted phenyl, wherein at least one substituent

CATHEPSIN CYSTEINE PROTEASE INHIBITORS

This invention relates to class of compounds which are cysteine protease inhibitors, including but not limited to, inhibitors of cathepsins K, L, S and B. These compounds are useful for treating diseases in which inhibition of bone resorption is indicated, such as osteoporosis. They have the following structure: Formula (I).

A new method for alkylation of aromatic aldehydes using alkylboron chloride derivatives in the presence of oxygen

Reactions of aromatic aldehydes with alkylboron chloride derivatives in the presence of oxygen have been investigated. Dialkylboron chlorides react with aryl aldehydes to produce arylalkylmethanols in good to excellent yields. Under the same reaction conditions, alkylboron dichlorides lead to the formation of arylalkyl chlorides.

Alkylation of aromatic aldehydes with alkylboron chloride derivatives

The reaction of aryl aldehydes with alkylboron chlorides has been investigated. Monoalkylboron dichlorides react with aryl aldehydes in hexane under reflux conditions to give a mixture of dichloroarylmethane and benzyl chloride. Under the same reaction conditions, dialkylboron chlorides lead to formation of a mixture of benzyl chloride and the chloroalkylation product. In the presence of a base such as 2,6-lutidine, the reactions of monoalkylboron dichlorides with aryl aldehydes yield small amounts of the desired alkylation products at room temperature. Dialkylboron chlorides react with aryl aldehydes in hexane in the presence of base to generate the corresponding arylalkylmethanols in good yields.

Heteroarylmethoxyphenylalkoxyiminoalkylcarboxylic acids as leukotriene biosynthesis inhibitors

A novel series of heteroarylmethoxyphenylalkoxyiminoalkylcarboxylic acids was studied as leukotriene biosynthesis inhibitors. A hypothesis of structure-activity optimization by insertion of an oxime moiety was investigated using REV-5901 as a starting point. A systematic structure- activity optimization showed that the spatial arrangement and stereochemistry of the oxime insertion unit proved to be important for inhibitory activity. The promising lead, S-(E)-11, inhibited LTB4 biosynthesis in the intact human neutrophil with IC50 of 8 nM and had superior oral activity in vivo, in a rat pleurisy model (ED50 = 0.14 mg/kg) and rat anaphylaxis model (ED50 = 0.13 mg/kg). In a model of lung inflammation, S-(E)-11 blocked LTE4 biosynthesis (ED50 of 0.1 mg/kg) and eosinophil influx (ED50 of 0.2 mg/kg). S-(E)-11 (A-93178) was selected for further preclinical evaluation.